{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:54:07Z","timestamp":1767135247801,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011709","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000}}],"reference-count":58,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011709.pub2","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T07:16:29Z","timestamp":1540970189000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chlorpromazine versus piperacetazine for schizophrenia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Mahin","family":"Eslami Shahrbabaki","sequence":"first","affiliation":[{"name":"Kerman University of Medical Sciences, Afzalipour School of Medicine; Neuroscience Research Centre, Institute of Neuropharmacology, Department of Psychiatry; Kerman Iran 7618834115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Dehnavieh","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Health Services Management Research Centre, Institute for Futures Studies in Health; Haft Bagh Road Kerman Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Vali","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Environmental Health Engineering Research Centre; Kerman Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahim","family":"Sharafkhani","sequence":"additional","affiliation":[{"name":"Khoy University of Medical Sciences; School of Health; Khoy Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD011709.pub2-BIB0001|cit1","first-page":"387","article-title":"Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients","volume":"12","author":"Gallant","year":"1970","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0002|cit2","first-page":"38","article-title":"Piperacetazine versus chlorpromazine (liquid)","volume":"7","author":"Gallant","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD011709.pub2-BIB0003|cit3","first-page":"101","article-title":"Piperacetazine versus chlorpromazine (tablet)","volume":"6","author":"Gallant","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0004|cit4","first-page":"55","article-title":"Piperacetazine (liquid) versus chlorpromazine","volume":"7","author":"Johnson","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD011709.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/ajp.130.5.603","article-title":"Piperacetazine and chlorpromazine: a comparison","volume":"130","author":"Johnson","year":"1973","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011709.pub2-BIB0006|cit6","first-page":"376","article-title":"Evaluation of piperacetazine (quide) injection in acute schizophrenics","volume":"14","author":"Kiev","year":"1972","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0007|cit7","first-page":"691","article-title":"Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study","volume":"9","author":"Kulkarni","year":"1974","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0033-3182(73)71335-9","article-title":"Comparative evaluation of injectable chlorpromazine and piperacetazine","volume":"14","author":"McLaughlin","year":"1973","journal-title":"Psychosomatics"},{"issue":"9","key":"10.1002\/14651858.CD011709.pub2-BIB0009|cit9","first-page":"574","article-title":"A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients","volume":"26","author":"Simeon","year":"1975","journal-title":"Hospital and Community Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0010|cit10","first-page":"57","article-title":"Piperacetazine versus Chlorpromazine-revision of summary reported on 2\/13\/70 with additional subjects","volume":"7","author":"Kurland","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD011709.pub2-BIB0011|cit11","first-page":"107","article-title":"Piperacetazine versus chlorpromazine","volume":"6","author":"Kurland","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0012|cit12","first-page":"52","article-title":"Piperacetazine (liquid) versus chlorpromazine","volume":"7","author":"Small","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1741-7015-3-15","article-title":"Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials","volume":"3","author":"Adams","year":"2005","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011709.pub2-BIB0015|cit15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD011709.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD011709.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.1971.03180180059011","article-title":"Evaluation of a new antipsychotic agent. Piperacetazine (quide)","volume":"215","author":"Anonymous","year":"1971","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD011709.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1207\/S15374424JCCP3102_04","article-title":"The target symptom rating: A brief clinical measure of acute psychiatric symptoms in children and adolescents","volume":"31","author":"Barber","journal-title":"Journal of Clinical Child and Adolescent Psychology"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011709.pub2-BIB0021|cit21","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"7","key":"10.1002\/14651858.CD011709.pub2-BIB0022|cit22","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007 Jul","journal-title":"Psychiatry (Edgmont)"},{"issue":"10","key":"10.1002\/14651858.CD011709.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0024|cit24","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Eight International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0025|cit25","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011709.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD011709.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD011709.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1532-5415.1976.tb03311.x","article-title":"Piperacetazine versus thioridazine in the treatment of organic brain disease: a controlled double-blind study","volume":"24","author":"Goldstein","year":"1976","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0034|cit34","unstructured":"Higgins JP Deeks JJ editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0035|cit35","unstructured":"Higgins JP Altman DG Sterne JA editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0037|cit37","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics","volume":"18","author":"Kishimoto","year":"2013","journal-title":"Molecular Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011709.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"11","key":"10.1002\/14651858.CD011709.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011709.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011709.pub2-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011709.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007778","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a re-examination","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011709.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0033-3182(72)71386-9","article-title":"Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients","volume":"13","author":"Rada","year":"1972","journal-title":"Psychosomatics"},{"issue":"4","key":"10.1002\/14651858.CD011709.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","article-title":"Size of burden of schizophrenia and psychotic disorders","volume":"15","author":"Rossler","year":"2005","journal-title":"European neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011709.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010631","article-title":"Chlorpromazine versus atypical antipsychotic drugs for schizophrenia","author":"Saha","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0052|cit52","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD011709.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD011709.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"A18","DOI":"10.1136\/bmjebm-2018-111024.36","article-title":"Gallstone, snake venom and witchcraft for schizophrenia: the challenges of classifying [schizophrenia] trials","volume":"23","author":"Shokraneh","year":"2018","journal-title":"Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD011709.pub2-BIB0055|cit55","unstructured":"Sterne JA Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD011709.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD011709.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD011709.pub2-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011709","article-title":"Chlorpromazine versus piperacetazine for schizophrenia","author":"Eslami Shahrbabaki","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011709.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:08:17Z","timestamp":1629454097000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011709.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011709.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}